RECRUITING

A 3-way Crossover Clinical Investigation to Assess the Performance of Two Different Sized Polyurethane Condoms Versus a Latex Condom in Healthy Monogamous Couples.

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This investigation is designed to evaluate the performance rate of two polyurethane male condoms with different sizes and thicknesses versus a standard natural rubber latex (NRL) male condom. The purpose of this study is to see how well the experimental condoms perform compared to the latex rubber condom (for example, how often the different condom types break or slip off the penis). Sponsor also wants to find out how well couples like using the three condom types and whether they experience any problems when using the condoms (for example, irritation or discomfort).

Official Title

A Randomized, Data Analyst-masked, 3-way Cross-over, Pivotal Clinical Investigation to Evaluate the Performance of Two Polyurethane Male Condoms With Different Size and Thickness in Healthy Monogamous Couples During Vaginal Intercourse Compared With a Commercially Available Thin Latex Male Condom.

Quick Facts

Study Start:2024-08-23

Study Completion:2025-05-19

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06557499

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 60 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
1. Both partners participating must provide written informed consent. 2. Couples must include a male and female within a heterosexual couple and be between 18 - 60 years of age inclusive. 3. Both partners must be willing to respond to questions about their reproductive and contraceptive history and use of condoms during interviews and respond to self-administered questionnaires as per instructions. 4. Both partners must agree to answer the questions in the condom use questionnaires and two scales as soon as possible and within 2 (+6) hours following each coital act. 5. Both partners must be generally healthy and in a mutually monogamous heterosexual relationship - current relationship ≥ 3 months. 6. All couples must be averaging one act of intercourse weekly, agree to have penile-vaginal intercourse with a frequency sufficient to meet CIP requirements (a minimum of 5 coital acts over 5 weeks per assessment period-). 7. The female partner must also use an established (as agreed by the Investigator) other highly effective form of non-barrier contraception, unless post-menopausal (confirmed menopausal prior to screening, amenorrhea for at least 12 months after cessation of exogenous hormone treatment) in which case no second form of contraception is required. Highly effective non-barrier contraception includes oral contraceptive (oestrogen and progestogen or progestogen-only hormonal contraception associated with inhibition of ovulation), intra-uterine device (IUD) or intra-uterine system (IUS), hormonal implant, injectables, patch and or sterilization of at least one partner (i.e., bilateral tubal ligation, vasectomy deemed medically successful). 8. Both partners must be able to understand instructions for correct use of condoms. 9. Both partners must have an adequate level of literacy to understand and to be able to answer the questionnaires. 10. Both partners must agree to use only the investigational condoms during the time of participation. 11. Participants must agree to use the penis measuring kit provided to measure the erect penis at investigation start. 12. Both partners must agree not to use drugs or non-investigational devices that can affect sexual performance. 13. Both partners must have no known sexually transmitted infections including Human Immunodeficiency Virus (HIV) / acquired immune deficiency syndrome (AIDS) (medical history via self-report). 14. Both partners must agree to use only lubricant(s) provided for the duration of investigation. 15. Both partners must agree not to wear any genital piercing jewellery for the duration of the clinical investigation. 16. Both partners must have no past medical history of any health condition (self-reported) that, in the opinion of the Investigator, would be considered clinically relevant. 17. Couples must have a compatible electronic device with internet access which they are willing to upload questionnaire data to the web-based platform throughout the investigation. 18. Both partners will be available for follow-up.	1. Either partner is or becomes aware of an allergy or sensitivity to the ingredients of any of the products, including the test or control condoms or any lubrication products provided. 2. Either partner has a pre-existing skin condition (for example, severe eczema/ psoriasis) as confirmed by the participants (self-reported). 3. Female partner that is pregnant or desires to become so while participating in investigation, (females of childbearing potential must have a negative pregnancy test as part of screening). 4. Any couple undergoing any form of fertility treatment such as in-vitro fertilisation. 5. Either partner needs to use condoms for sexually transmitted infection (STI) protection (e.g., discordance for Human Immunodeficiency Virus (HIV) or herpes). 6. Either partner has previous or planned genital surgery that in the opinion of the Investigator would consider the participant unsuitable to participate in the clinical investigation (e.g., laser for abnormal smear). 7. Either partner are commercial sex workers. 8. Either partner are itinerant persons who will be unable to complete the clinical investigation (e.g., migrant farm workers). 9. Couples that in the opinion of the Investigator, would be unable to complete the investigation. 10. Male partners that have known erectile or ejaculatory dysfunction in the past month. 11. Either partner requires to use/ is using medication or preparations that are applied topically to the genitalia area or intravaginally, other than that supplied for the investigation. 12. A female partner that has been diagnosed with or treated for vaginal complaints (including vaginal dryness) in the previous 3 months which, in the opinion of the Investigator, deems the partner unsuitable for the investigation. 13. Either partner uses any medication which in the investigator's opinion may interfere with the use of condoms. 14. A male partner with abnormal penile anatomy or genital lesion (e.g., balanoposthitis) that would, in the opinion of the Investigator, affect the ability to keep the condom in place during intercourse. 15. Either partner is suffering from any health conditions (self-reported) or any condition which could, in the opinion of the Investigator, affect the outcome of the investigation or affect their safety if they participate. 16. Either partner have participated in a clinical trial in the previous month which could, in the opinion of the Investigator, affect the outcome of the investigation. 17. Either partner is an employee of the investigational Sponsor or affiliated with the clinical research centre (i.e., enrolment of the Investigator, his/ her family members, employees and other dependent persons). 18. Either partner has a known or suspected history of drug or alcohol abuse. 19. Either partner has an inability to follow the procedures of the investigation, (e.g., due to language problems, psychological disorders, health conditions such as dementia). 20. Either partner is unable, in the opinion of the Investigator, to fully comply with the investigation requirements.

Inclusion Criteria

Exclusion Criteria

1. Both partners participating must provide written informed consent.
2. Couples must include a male and female within a heterosexual couple and be between 18 - 60 years of age inclusive.
3. Both partners must be willing to respond to questions about their reproductive and contraceptive history and use of condoms during interviews and respond to self-administered questionnaires as per instructions.
4. Both partners must agree to answer the questions in the condom use questionnaires and two scales as soon as possible and within 2 (+6) hours following each coital act.
5. Both partners must be generally healthy and in a mutually monogamous heterosexual relationship - current relationship ≥ 3 months.
6. All couples must be averaging one act of intercourse weekly, agree to have penile-vaginal intercourse with a frequency sufficient to meet CIP requirements (a minimum of 5 coital acts over 5 weeks per assessment period-).
7. The female partner must also use an established (as agreed by the Investigator) other highly effective form of non-barrier contraception, unless post-menopausal (confirmed menopausal prior to screening, amenorrhea for at least 12 months after cessation of exogenous hormone treatment) in which case no second form of contraception is required. Highly effective non-barrier contraception includes oral contraceptive (oestrogen and progestogen or progestogen-only hormonal contraception associated with inhibition of ovulation), intra-uterine device (IUD) or intra-uterine system (IUS), hormonal implant, injectables, patch and or sterilization of at least one partner (i.e., bilateral tubal ligation, vasectomy deemed medically successful).
8. Both partners must be able to understand instructions for correct use of condoms.
9. Both partners must have an adequate level of literacy to understand and to be able to answer the questionnaires.
10. Both partners must agree to use only the investigational condoms during the time of participation.
11. Participants must agree to use the penis measuring kit provided to measure the erect penis at investigation start.
12. Both partners must agree not to use drugs or non-investigational devices that can affect sexual performance.
13. Both partners must have no known sexually transmitted infections including Human Immunodeficiency Virus (HIV) / acquired immune deficiency syndrome (AIDS) (medical history via self-report).
14. Both partners must agree to use only lubricant(s) provided for the duration of investigation.
15. Both partners must agree not to wear any genital piercing jewellery for the duration of the clinical investigation.
16. Both partners must have no past medical history of any health condition (self-reported) that, in the opinion of the Investigator, would be considered clinically relevant.
17. Couples must have a compatible electronic device with internet access which they are willing to upload questionnaire data to the web-based platform throughout the investigation.
18. Both partners will be available for follow-up.

1. Either partner is or becomes aware of an allergy or sensitivity to the ingredients of any of the products, including the test or control condoms or any lubrication products provided.
2. Either partner has a pre-existing skin condition (for example, severe eczema/ psoriasis) as confirmed by the participants (self-reported).
3. Female partner that is pregnant or desires to become so while participating in investigation, (females of childbearing potential must have a negative pregnancy test as part of screening).
4. Any couple undergoing any form of fertility treatment such as in-vitro fertilisation.
5. Either partner needs to use condoms for sexually transmitted infection (STI) protection (e.g., discordance for Human Immunodeficiency Virus (HIV) or herpes).
6. Either partner has previous or planned genital surgery that in the opinion of the Investigator would consider the participant unsuitable to participate in the clinical investigation (e.g., laser for abnormal smear).
7. Either partner are commercial sex workers.
8. Either partner are itinerant persons who will be unable to complete the clinical investigation (e.g., migrant farm workers).
9. Couples that in the opinion of the Investigator, would be unable to complete the investigation.
10. Male partners that have known erectile or ejaculatory dysfunction in the past month.
11. Either partner requires to use/ is using medication or preparations that are applied topically to the genitalia area or intravaginally, other than that supplied for the investigation.
12. A female partner that has been diagnosed with or treated for vaginal complaints (including vaginal dryness) in the previous 3 months which, in the opinion of the Investigator, deems the partner unsuitable for the investigation.
13. Either partner uses any medication which in the investigator's opinion may interfere with the use of condoms.
14. A male partner with abnormal penile anatomy or genital lesion (e.g., balanoposthitis) that would, in the opinion of the Investigator, affect the ability to keep the condom in place during intercourse.
15. Either partner is suffering from any health conditions (self-reported) or any condition which could, in the opinion of the Investigator, affect the outcome of the investigation or affect their safety if they participate.
16. Either partner have participated in a clinical trial in the previous month which could, in the opinion of the Investigator, affect the outcome of the investigation.
17. Either partner is an employee of the investigational Sponsor or affiliated with the clinical research centre (i.e., enrolment of the Investigator, his/ her family members, employees and other dependent persons).
18. Either partner has a known or suspected history of drug or alcohol abuse.
19. Either partner has an inability to follow the procedures of the investigation, (e.g., due to language problems, psychological disorders, health conditions such as dementia).
20. Either partner is unable, in the opinion of the Investigator, to fully comply with the investigation requirements.

Contacts and Locations

Study Contact

Terri Walsh

CONTACT

+1 213 386 5614

twalsh@essentialaccess.org

Principal Investigator

Terri Walsh

PRINCIPAL_INVESTIGATOR

Essential Access Health

Study Locations (Sites)

Essential Access Health-Berkeley

Berkeley, California, 90010

United States

Essential Access Health -Los Angeles

Los Angeles, California, 90010

United States

Essential Acess Health- Seattle

Seattle, Washington, 98005

United States

Collaborators and Investigators

Sponsor: Reckitt Benckiser Healthcare (UK) Limited

Terri Walsh, PRINCIPAL_INVESTIGATOR, Essential Access Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-08-23

Study Completion Date2025-05-19

Study Record Updates

Study Start Date2024-08-23

Study Completion Date2025-05-19

Terms related to this study

Keywords Provided by Researchers

Condoms
Slippage
Breakage

Additional Relevant MeSH Terms

Contraception